Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia (OPTION-A)
Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE™ PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care during the same procedure.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The OPTION-A Study is an observational, prospective, single-arm, multi-center non-mandated post-market study. Subjects enrolled in the OPTION-A study will be clinically indicated for atrial fibrillation (AF) ablation procedure with the FARAPULSE PFA system and treatment with WATCHMAN LAAC Device, per physician's medical judgement and according to hospitals' standard of care. The objective(s) of the OPTION-A Study is to evaluate safety and effectiveness of catheter ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent implant of Left Atrial Appendage closure (LAAC) with the WATCHMAN™ LAA Closure device in a concomitant procedure.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Locais de estudo
-
-
-
Beijing, China
- Xuanwu Hospital Capital Medical University
-
Beijing, China
- Beijing Anzhen Hospital of the Capital University of Medical Sciences
-
Chengdu, China
- Huaxi Hospital of Sichuan University
-
Chengdu, China
- The First Affiliated Hospital of Chengdu Medical College
-
Guangzhou, China
- The Third Affiliated Hospital of Guangzhou Medical University
-
Guangzhou, China
- Guangdong Nanfang Hospital
-
Guiyang, China
- The Affiliated Hospital of Guizhou Medical University
-
Hangzhou, China
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
-
Jinan, China
- QiLu Hospital of ShanDong University
-
Kunming, China
- First People's Hospital of Yunnan Province
-
Nantong, China
- Affiliated Hospital of Nantong University
-
Taiyuan, China
- Shanxi Cardiovascular Hospital
-
Zhuhai, China
- Zhuhai People's Hospital
-
Zigong, China
- Zigong First People's Hospital
-
-
Jiangsu
-
Suzhou, Jiangsu, China
- The First Affiliated Hospital of Soochow University
-
-
-
-
-
Singapore, Cingapura
- Asian Heart and Vascular Centre
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Kowloon, Hong Kong
- Queen Elizabeth Hospital
-
-
-
-
-
Fukuoka-ken, Japão
- Kokura Memorial Hospital
-
Kanagawa, Japão
- Yokosuka Kyosai Hospital
-
Kawasaki, Japão
- Kawasaki Saiwai Hospital
-
Meguro-ku, Japão
- Toho University Ohashi Medical Center
-
Osaka, Japão
- Osaka Keisatsu Hospital
-
Yokohama, Japão
- Yokohama city minato Red Cross Hospital
-
-
Kanagawa
-
Kamakura-shi, Kanagawa, Japão
- Shonan Kamakura General Hospital
-
-
Miyagi
-
Sendai, Miyagi, Japão
- Sendai Kousei Hospital
-
-
Okayama Kurashiki-shi
-
Kurashiki-shi, Okayama Kurashiki-shi, Japão
- Kurashiki Central Hospital
-
-
Saitama
-
Saitama, Saitama, Japão
- Saitama Red Cross Hospital
-
-
Tokyo
-
Fuchu-shi, Tokyo, Japão
- Sakakibara Heart Institute, Sakakibara Heart Foundation
-
-
-
-
-
Kuala Lumpur, Malásia
- Institute Jantung Negara
-
Kuching, Malásia
- Pusat Jantung Sarawak
-
-
-
-
-
Taichung, Taiwan
- China Medical University Hospital
-
Taichung, Taiwan
- Taichung Veterans General Hospital
-
Taipei, Taiwan
- National Taiwan University Hospital
-
Taipei, Taiwan
- Taipei Veterans General Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Subjects enrolled in the OPTION-A study will be clinically indicated for an Atrial Fibrillation ablation procedure utilizing the FARAPULSE PFA System as well as implantation of the WATCHMAN device per physician's medical judgement, and according to the hospitals' standard of care during the same procedure. The subjects selected for participation in the study will be from the investigator's general patient population. The investigator or designee has the responsibility for screening all potential subjects and selecting those who meet study eligibility criteria.
Descrição
Inclusion Criteria:
- Clinically indicated for treatment with both the FARAPULSE™ PFA system and with WATCHMAN for LAAC, per physician medical judgement and as per hospitals' standard of care.
- Subjects who are willing and able to provide informed consent.
- Subjects who are willing and able to participate in all testing associated with this clinical study at an approved clinical investigational center.
- Subjects whose age is 18 years or above, or who are of legal age to give informed consent specific to state and national law.
Exclusion Criteria:
- Subjects who underwent prior AF ablation procedure.
- Subjects with atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible / non-cardiac causes.
- Already surgically closed or otherwise excluded LAA.
- The LAA anatomy does not accommodate a Closure Device.
- Known or suspected atrial myxoma.
- Presence of intracardiac thrombus.
- Subjects with a current interatrial baffle or patch, history of atrial septal repair or has an ASD/PFO device.
- Subjects with a presence of a mechanical valve prosthesis in any position.
- Subjects with a myocardial infarction within 30 days prior to enrollment.
- Subjects had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 90 days prior to enrollment.
- Any planned electrical cardioversion within 30 days following LAAC device implant.
- Subjects with a known inability to obtain vascular access.
- Subjects with any contraindication to percutaneous catheterization procedure (e.g., patient size does not accommodate required catheters, ventriculotomy or atriotomy), active conditions (e.g. infection, bleeding disorder, unstable angina) or congenital abnormalities (severe rotational anomalies of the heart or great vessels) are present*.
- Subjects with any active conditions (e.g. infection, bleeding disorder, unstable angina) are present.
- Subjects with any contraindications to short term use of anticoagulation therapy, or aspirin for conditions different from atrial fibrillation.
- Subjects who are pregnant or planning to be pregnant.
- Subjects with a life expectancy of ≤ 1 year per investigator's opinion.
- Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be reviewed by the sponsor to determine eligibility.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Treatment Subjects
A subject is considered enrolled once an approved informed consent form has been signed and dated. Enrolled Subjects will undergo AF ablation procedure with the FARAPULSE PFA System, followed by WATCHMAN implant during the same procedure. |
The FARAPULSE™ PFA System consists of the FARAWAVE™ Pulsed Field Ablation Catheter, the FARASTAR™ Pulsed Field Ablation Generator, and the FARADRIVE™ Steerable Sheath. The WATCHMAN LAA Closure Technology consists of the WATCHMAN Access System (which consists of the Access Sheath and Dilator and the WATCHMAN Delivery System (which consists of the delivery catheter and the pre-loaded closure device). The WATCHMAN Access System and WATCHMAN Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Periprocedural or procedure-related Composite Serious Adverse Events will be assessed
Prazo: 30 days post index procedure
|
The primary safety endpoint (PSE) is the proportion of subjects with one or more of the periprocedural device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 30 days following the Index Procedure. |
30 days post index procedure
|
|
Acute Treatment Success will be assessed
Prazo: between index procedure and 30 days post index procedure
|
The primary effectiveness endpoint (PEE) is the proportion of subjects with Acute Treatment Success assessed among those receiving ≥1 PFA application and who have a WATCHMAN attempted or implanted. |
between index procedure and 30 days post index procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed
Prazo: 1 year post index procedure
|
Device or procedure-related Composite Serious Adverse Events (CSAEs) assessed at 360 days following the Index Procedure |
1 year post index procedure
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PF316
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .